Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose synchronized cyclophosphamide for recurrent ovarian cancer
ACTRN12608000013369Phase 2Not yet recruiting
- Sponsor
- The Royal Women's Hospital
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in ovarian cancer, sponsored by The Royal Women's Hospital. Primary endpoints: Tumor response and CA125 response. Planned start Mar 2008; status: not yet recruiting.
02
Drugs
cyclophosphamide
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ACTRN12608000013369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000013369.